Lipid-lowering drugs and heart failure: Where do we go after the statin trials?

Current Opinion in Cardiology

Volumn 25, Issue 4, 2010, Pages 385-393

  Strandberg, Timo E ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

HDL cholesterol; heart failure; LDL cholesterol; statin

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSLIPIDEMIA; HEART FAILURE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HUMAN; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; PROGNOSIS; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DISEASE PROGRESSION; HEART FAILURE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; PRAVASTATIN; PRIMARY PREVENTION; PROGNOSIS; PYRROLES; RISK FACTORS; SECONDARY PREVENTION; TRIGLYCERIDES;

EID: 77953809372     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328338bc2d     Document Type: Review

References (44)

1. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348:2007-2018.
2. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008; 29:2388-2442.
3. AHA Scientific Statement. Prevention of heart failure. Circulation 2008; 117:2544-2565.
4. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278.
5. Sipahi I, Nicholls SJ, Tuzcu EM, Nissen SE. Coronary atherosclerosis can regress with very intensive statin therapy. Cleve Clin J Med 2006; 73:937-944.
6. Horwich TB, Hernandez AF, Dai D, et al. Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. Am Heart J 2008; 156:1170-1176.
7. Gü der G, Frantz S, Bauersachs J, et al. Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic benefit of classical cardiovascular risk factors. Circ Heart Fail 2009; 2:563-571.
8. Charach G, George J, Roth A, et al. Baseline low-density lipoprotein cholesterol levels and outcome in patients with heart failure. Am J Cardiol 2010; 105:100-104.
9. Martin JH, Krum H. Statins and clinical outcomes in heart failure. Clin Sci (Lond) 2007; 113:119-127. (Pubitemid 47237908)
10. Ramasubbu K, Estep J, White DL, et al. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008; 51:415-426.
11. Gomes ME, Lenders JW, Bellersen L, et al. Sympathoinhibitory effect of statins in chronic heart failure. Clin Auton Res 2009. [Epub ahead of print]
12. Kanapuru B, Ershler WB. Inflammation, coagulation, and the pathway to frailty. Am J Med 2009; 122:605-613.
13. Pel-Littel RE, Schuurmans MJ, Emmelot-Vonk MH, et al. Frailty: defining and measuring of a concept. J Nutr Health Aging 2009; 13:390-394.
14. Velagaleti RS, Massaro J, Vasan RS, et al. Relations of lipid concentrations to heart failure incidence: the Framingham Heart Study. Circulation 2009; 120:2345-2351.
15. Wojnicz R, Wilczek K, Nowalany-Kozielska E, et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 2006; 97:899-904.
16. Sever PS, Poulter NR, Dahlof B, et al. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J 2008; 29:499-508.
17. Heart Protection Study Collaborative Group. N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J Am Coll Cardiol 2007; 49:311-319.
18. Kjekshus J, Pedersen TR, Olsson AG, et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997; 3:249-254. (Pubitemid 127674856)
19. Lewis EF, Moye LA, Rouleau JL, et al. Predictors of late development of heart failure in stable survivors of myocardial infarction. The CARE Study. J Am Coll Cardiol 2003; 42:1446-1453.
20. Aronow WS, Ahn C. Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol 2002; 90:147-149. (Pubitemid 34775124)
21. Khush K, Waters D, Bittner V, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 2007; 115:576-583.
22. Strandberg TE, Holme I, Faergeman O, et al., for the IDEAL Study Group. Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction. Am J Cardiol 2009; 103:1381-1385.
23. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study. Lancet 1994; 344:1383-1389.
24. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357:2248-2261.
25. GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1231-1239.
26. Scirica BM,Morrow DA, Cannon CP, et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006; 47:2326.
27. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs. a delayed conservative simvastatin therapy in patients with acute coronary syndromes: phase Z of A to Z trial. J Am Med Assoc 2004; 292:1307-1316.
28. Wedel H, McMurray JJ, Lindberg M, et al., for the CORONA Study Group. Predictors of fatal and nonfatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail 2009; 11:281-291.
29. Cleland JG, McMurray JJ, Kjekshus J, et al., for the CORONA Study Group. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 2009; 54:1850- 1859.
30. Lorgelly PK, Briggs AH, Wedel H, et al., for the CORONA Study Group. An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. Eur J Heart Fail 2010; 12:66-74.
31. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1223-1230.
32. Athyros VG, Kakafika AI, Tziomalos K, et al. CORONA, statins, and heart failure: who lost the crown? Angiology 2008; 59:5-8.
33. van der Harst P, Voors AA, van Gilst WH, et al. Statins in the treatment of chronic heart failure: a systematic review. PLoS Med 2006; 3:e333.
34. Go A, Lee W, Yang J, et al. Statin therapy and risks of death and hospitalization in chronic heart failure. J Am Med Assoc 2006; 296:2105-2111.
35. Ryan RP,McManus RJ, Mant J, et al. Statins in heart failure: retrospective cohort study using routine primary care data. Ann Med 2009. [Epub ahead of print]
36. Wang J, Sarnola K, Ruotsalainen S, et al. The metabolic syndrome predicts incident congestive heart failure: a 20-year follow-up study of elderly Finns. Atherosclerosis 2009. [Epub ahead of print]
37. AlZadjali MA, Godfrey V, Khan F, et al. Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure. J Am Coll Cardiol 2009; 53:747-753.
38. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341:410-418.
39. Olsson AG. Is high HDL cholesterol always good? Ann Med 2009; 41:11-18.
40. Hausenloy DJ, Yellon DM. Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels. Curr Opin Cardiol 2009; 24:473-482.
41. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009; 361:2113-2222.
42. Kerola T, Nieminen T, Hartikainen S, et al. High-density lipoprotein is superior to B-type natriuretic peptide as a marker of systolic dysfunction in an elderly general population. Scand J Clin Lab Invest 2009; 69:865-872.
43. Mehra MR, Uber PA, Lavie CJ, et al. High-density lipoprotein cholesterol levels and prognosis in advanced heart failure. J Heart Lung Transplant 2009; 28:876-880.
44. Holme I, Strandberg TE, Faergeman O, et al., for the IDEAL Study Group. Congestive heart failure is associated with lipoprotein components in statintreated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL). Atherosclerosis 2009; 205:522-527.